Predictive Factors for Central Nervous System Involvement in Non-Hodgkin's Lymphoma: Significance of Very High Serum LDH Concentrations

Factors predictive for central nervous system (CNS) involvement at presentation were investigated in 152 patients with non-Hodgkin's lymphoma (NHL) except for lymphoblastic cell lymphoma and small noncleaved cell lymphoma. Twelve patients developed CNS involvement during their disease course. The incidence was 7.9% of all the patients studied and 17.0% of the patients with serum LDH concentration two times the upper limit of normal (2N). By univariate analysis, stage IV disease (P =. 023), a serum LDH concentration S2N (P =. 009), and bone marrow involvement (P =. 016) were risk factors for CNS involvement. Multivariate logistic regression analysis identified a serum LDH concentration 2 N (P =. 032) as an independent predictor for CNS involvement. All 12 patients who developed CNS involvement were among the 126 patients with diffuse lymphoma, whereas none of the 17 patients with follicular lymphoma developed CNS involvement, although the difference was not statistically significant. The median survival of the patients with CNS involvement was only 4.5 months. We conclude that a serum LDH concentration 2N at presentation is a significant predictive factor for CNS involvement for NHL patients without lymphoblastic lymphoma and small noncleaved cell lymphoma. Therefore, we would suggest that CNS prophylaxis should be considered for patients with a serum LDH concentration 2N at presentation and diffuse lymphoma once a complete remission is achieved.

[1]  F. Cabanillas,et al.  Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis. , 1979, Blood.

[2]  P. Mclaughlin,et al.  Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. , 1998, Blood.

[3]  R. Liang,et al.  Secondary central nervous system involvement by non‐Hodgkin's lymphoma: The risk factors , 2006, Hematological oncology.

[4]  K. Thorling,et al.  Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis. , 1996, Acta oncologica.

[5]  N. Keiding,et al.  Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. , 2009, Scandinavian journal of haematology.

[6]  B. Telek,et al.  [Involvement of the central nervous system in non-Hodgkin's lymphoma]. , 1986, Orvosi hetilap.

[7]  T. Colby,et al.  Central nervous system involvement in non‐Hodgkin's lymphoma: An analysis of 105 cases , 1982, Cancer.

[8]  D. Rosenthal,et al.  CNS involvement in the non‐hodgkin's lymphomas , 1980, Cancer.

[9]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[10]  D. Weisenburger,et al.  Central Nervous System Involvement in Patients with Diffuse Aggressive Non‐Hodgkin's Lymphoma , 1991, American journal of clinical oncology.

[11]  M. Oken,et al.  CENTRAL NERVOUS SYSTEM RELAPSE IN UNFAVOURABLE-HISTOLOGY NON-HODGKIN'S LYMPHOMA: IS PROPHYLAXIS INDICATED? , 1984, The Lancet.

[12]  L. Recht,et al.  Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis. , 1988, The American journal of medicine.

[13]  J. Hermans,et al.  Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. , 1997, Archives of neurology.

[14]  S. Jones,et al.  Involvement of the central nervous system by non‐Hodgkin's lymphoma. The southwest oncology group experience , 1979, Cancer.

[15]  National cancer institute sponsored study of classifications of non‐hodgkin's lymphomas. Summary and description of a working formulation for clinical usage , 2022 .